Synthesis and structure-activity relationships of novel 2',2'-difluoro analogues of docetaxel

Chemical and Pharmaceutical Bulletin

Volumn 45, Issue 11, 1997, Pages 1793-1804

  Uoto, Kouichi ^a   Ohsuki, Satoru ^a   Takenoshita, Haruhiro ^a   Ishiyama, Takashi ^a   Iimura, Shin ^a   Hirota, Yasuhide ^a   Mitsui, Ikuo ^a   Terasawa, Hirofumi ^a   Soga, Tsunehiko ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

2',2 Difluro analogue; Cytotoxicity; Docetaxel; Microtubule disassembly inhibitory activity; Paclitaxel; Structure activity relationship

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; DOCETAXEL; PACLITAXEL DERIVATIVE; TERPENOID;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ESTERIFICATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MASS SPECTROMETRY; MICROTUBULE ASSEMBLY; NONHUMAN; PHYSICAL CHEMISTRY; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

EID: 0031390567     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.45.1793     Document Type: Article

References (40)

1. Wani M. C. Taylor H. L., Wall M. E., Cohort P., McPhail A. T., J. Am. Chem. Soc., 93, 2325-2327 (1971).
2. Gueritte-Voegelein F., Guenard D., Lavelle F., Le Goff M.-T., Mangatal L., Potier P., J. Med. Chem., 34, 992-998 (1991).
3. "Taxane Anticancer Agents: Basic Science and Current Status", ed. by George G. I., Chen T. T., Ojima I., Vyas D. M., American Chemical Society: Washington DC 1995.
4. a) Schiff P. B., Fant J., Horwitz S. B., Nature (London), 277, 665-667 (1979);
5. b) Schiff P. B., Horwitz S. B., Proc., Natl. Acad. Sci. U.S.A., 77, 1561-1565 (1980).
6. a) Rowinsky E. B., Seminars in Oncology, 19, 646-662 (1992);
7. b) Verweij J., Clavel M., Chevalier B., Ann. Oncol., 5, 495-505 (1994).
8. a) Parness J., Kingston D. G. I., Powell R. G., Harracksingh C., Horwitz S. B., Biochem. Biophys. Res. Commun., 105, 1082-1089 (1982);
9. b) Kingston D. G. I., Magri N. F. J., Nat. Prod., 51, 298-306 (1988);
10. c) Horwitz S. B., Mellado W., Magri N. F., Kingston D. G. I., Garcia-Arenas R., Orr G. A., Biochem. Biophys. Res. Commun., 124, 329-336 (1984).
11. a) Georg G. I., Cheruvallath Z. S., Himes R. H., Mejillano M. R., Burke C. T., J. Med. Chem., 35, 4230-4237 (1992);
12. b) Georg G. I., Cheruvallath Z. S., Himes R. H., Mejillano M. R., Bioorg. Med. Chem. Lett., 2, 295-298 (1992);
13. c) Idem., ibid., 2, 1751-1754 (1992);
14. d) Swindell C. S., Heerding J. M., Krauss N. E., Horwitz S. B., Ringer I., ibid., 4, 1531-1536 (1994);
15. e) Hollon R. A., Nadizadeh H., Kim S., Beidiger R. J., U. S. Patent, 5.250.683, 1993 [Chem. Abstr., 119, 49694u (1994)];
16. e) Hollon R. A., Nadizadeh H., Kim S., Beidiger R. J., U. S. Patent, 5.250.683, 1993 [Chem. Abstr., 119, 49694u (1994)];
17. f) Idem, J., Eur. Patent Appl. 534708-A1, 1993 [Chem. Abstr., 119, 49693t (1994)];
18. f) Idem, J., Eur. Patent Appl. 534708-A1, 1993 [Chem. Abstr., 119, 49693t (1994)];
19. g) Georg G. I., Harriman G. C. B., Hepperle M., Himes R. H., Bioorg. Med. Chem. Lett., 4, 1381-1384 (1994);
20. h) Bourzat J. D., Commercon A., Tetrahedron Lett., 34, 6049-6052 (1993).
21. 2′-Fluoropaclitaxel: Kant J., Huang S., Wong H., Fairchild C., Vyas D., Farina V., Bioorg. Med. Chem. Lett., 3, 2471-2474 (1993).
22. Mangatal L., Adeline M. T., Guenard D., Gueritte-Voegelein F., Potier P., Tetrahedron, 45, 4177-4190 (1989).
23. a) Hallina E. A., Fried J., Tetrahedron Lett., 25, 2301-2302 (1984);
24. b) Lindermann R. J., Graves D. M., J. Org. Chem., 54, 661-668 (1989).
25. Taguchi T., Kitagawa O., Suda Y., Ohkawa S., Hashimoto A., Iitaka Y., Kobayashi Y., Tetrahedron Lett., 31, 5291-5294 (1988).
26. Ojima I., Hahus I., Zhao M., Zucco M., Park Y. H., Sun C. M., Brigaud T., Tetrahedron, 48, 6985-7012 (1992).
27. Thaisrivongs S., Schostarez H. J., Pals D. T., Turner S. R., J. Med. Chem., 30, 1837-1842 (1987).
28. Kim S., Lee J. T., Ko Y. K., Tetrahedron Lett., 25, 4943-4946 (1984).
29. Greene A. E., Denis J. -N., Guenard D., Guerilte-Voegelein F., Mangatal L., Potier P., J. Am. Chem. Soc., 110, 5917-5919 (1988).
30. a) Saloma D., Linnantie R., Acta Chem. Scand., 14, 777-781 (1960);
31. b) Jacobson R. M., Clader J. W., Synth. Commun., 9, 57-62 (1979).
32. The resolution of (±)-10a with preparative HPLC was performed by Daicel Chemical Industries, Ltd.
33. Welch J. T., Araki K., Kawecki R., Wichtowski J. A., J. Org. Chem., 58, 2454-2462 (1993).
34. Falzone C. J., Benesi A. J., Lecomte J. T., Tetrahedron Lett., 33, 1169-1172 (1992).
35. Kant J., Huitng S., Wong H., Fairchild C., Vyas D., Farina V., Bioorg. Med. Chem. Lett., 3, 2471-2474 (1993).
36. Curran T. T., J. Org. Chem., 58, 6360-6363 (1993).
37. The X-ray crystal structure analysis of 24a was performed by M. Suzuki of the Basic Technology Research Laboratory of Daiichi Pharmaceutical Co., Ltd.
38. Alley M. C., Scudiero D. A., Monks A., Hursey M. L., Czerwinski M. J., Fine D. L., Abbott B. J., Mayo J. G., Shoemaker R. H., Boyd M. R., Cancer Res., 48, 589-601 (1988).
39. a) Gaskin F., Cantor C. R., Shelanski M. L., J. Mol. Biol., 89, 737-755 (1974);
40. b) Shelanski M. L., Gaskin F., Cantor C. R., Proc. Natl. Acad. Sci. U.S.A., 70, 765-768 (1973).